Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5179907 | 0.93 | TSHR (0.39) | TSHRALDH1A1HPGD | |
| SCHEMBL22654287 | 0.92 | TSHR (0.37) | TSHRALDH1A1HPGD | |
| SCHEMBL460505 | 0.88 | TSHR (0.34) | TSHRALDH1A1HPGD | |
| SCHEMBL460504 | 0.88 | TSHR (0.34) | TSHRALDH1A1HPGD | |
| SCHEMBL3338598 | 0.84 | TSHR (0.33) | TSHRALDH1A1 | |
| SCHEMBL3902659 | 0.83 | TSHR (0.39) | TSHRALDH1A1HPGDPLA2G2CCA1 | |
| SCHEMBL9252663 | 0.83 | TSHR (0.39) | TSHRALDH1A1HPGDPLA2G2CCA1 | |
| SCHEMBL9009705 | 0.81 | TSHR (0.43) | TSHRALDH1A1PLA2G2CCA1CA2 | |
| SCHEMBL22654290 | 0.81 | TSHR (0.38) | TSHRALDH1A1HPGD | |
| SCHEMBL4579212 | 0.81 | TSHR (0.43) | TSHRALDH1A1PLA2G2CCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373550-A1 | METHOD OF PREPARING SUPPORTED LIPID FILM MEMBRANES AND USE THEREOF | Biacore AB (SE) | 2004-01-02 | — | — | EP | claimed |
| US-20020182717-A1 | Method of preparing supported lipid film membranes and use thereof | BIACORE AB (SE) | 2002-12-05 | — | — | US | claimed |
| WO-2002072873-A1 | METHOD OF PREPARING SUPPORTED LIPID FILM MEMBRANES AND USE THEREOF | BIACORE AB (SE) | 2002-09-19 | — | — | WO | claimed |
| EP-0483465-B1 | Long chain di(acyloxy)dialkylsilanes, di(acyloxy)diarylsilanes, di(acyloxy)dialkoxysilanes, and tetra(acyloxy)silanes, process for their preparation, their use for the preparation of vesicles, so produced vesicles and their use as vehicles for drugs | SALAMA ZOSER BOULIS DR (DE) | 1995-08-02 | — | — | EP | claimed |
| EP-0483465-A1 | Long chain di(acyloxy)dialkylsilanes, di(acyloxy)diarylsilanes, di(acyloxy)dialkoxysilanes, and tetra(acyloxy)silanes, process for their preparation, their use for the preparation of vesicles, so produced vesicles and their use as vehicles for drugs | Salama, Zoser Boulis, Dr. (DE) | 1992-05-06 | — | — | EP | claimed |
| US-11912889-B2 | Silicon-containing polymer, film-forming composition, method for forming silicon-containing polymer coating, method for forming silica coating, and production method for silicon-containing polymer | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-20220220338-A1 | SILICON-CONTAINING POLYMER, FILM-FORMING COMPOSITION, METHOD FOR FORMING SILICON-CONTAINING POLYMER COATING, METHOD FOR FORMING SILICA COATING, AND PRODUCTION METHOD FOR SILICON-CONTAINING POLYMER | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-07-14 | — | — | US | disclosed |
| US-20220213348-A1 | SILICON-CONTAINING POLYMER, FILM-FORMING COMPOSITION, METHOD FOR SUPPORTING METAL COMPOUND ON SURFACE OF OBJECT TO BE TREATED, ARTICLE HAVING METAL COMPOUND-SUPPORTING COATING FILM, AND METHOD FOR PRODUCING SILICON-CONTAINING POLYMER | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-07-07 | — | — | US | disclosed |
| US-11377522-B2 | Silicon-containing polymer, film-forming composition, method for forming silicon-containing polymer coating, method for forming silica-based coating, and production method for silicon-containing polymer | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-07-05 | — | — | US | disclosed |
| EP-3971229-A1 | SILICON-CONTAINING POLYMER, FILM-FORMING COMPOSITION, METHOD FOR FORMING SILICON-CONTAINING POLYMER COATING, METHOD FOR FORMING SILICA COATING, AND PRODUCTION METHOD FOR SILICON-CONTAINING POLYMER | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-03-23 | — | — | EP | disclosed |
| EP-3957678-A1 | SILICON-CONTAINING POLYMER, FILM-FORMING COMPOSITION, METHOD FOR SUPPORTING METAL COMPOUND ON SURFACE OF OBJECT TO BE TREATED, ARTICLE HAVING METAL COMPOUND-SUPPORTING COATING FILM, AND METHOD FOR PRODUCING SILICON-CONTAINING POLYMER | Tokyo Ohka Kogyo Co., Ltd. (JP) | 2022-02-23 | — | — | EP | disclosed |
| US-11241393-B2 | Organosilicon carriers for use in treating infections and/or diseases caused by SARS viruses | SALAMA ZOSER B (DE) | 2022-02-08 | — | — | US | disclosed |
| EP-1188058-A2 | METHOD AND APPARATUS FOR ASSAYING A DRUG CANDIDATE TO ESTIMATE A PHARMACOKINETIC PARAMETER ASSOCIATED THEREWITH | Biacore AB (SE) | 2002-03-20 | — | — | EP | disclosed |
| US-20020019019-A1 | Method and apparatus for assaying a drug candidate to estimate a pharmacokinetic parameter associated therewith | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2002-02-14 | — | — | US | disclosed |
| WO-2000079268-A2 | METHOD AND APPARATUS FOR ASSAYING A DRUG CANDIDATE TO ESTIMATE A PHARMACOKINETIC PARAMETER ASSOCIATED THEREWITH | BIACORE AB (SE) | 2000-12-28 | — | — | WO | disclosed |
| EP-0483465-B1 | Long chain di(acyloxy)dialkylsilanes, di(acyloxy)diarylsilanes, di(acyloxy)dialkoxysilanes, and tetra(acyloxy)silanes, process for their preparation, their use for the preparation of vesicles, so produced vesicles and their use as vehicles for drugs | SALAMA ZOSER BOULIS DR (DE) | 1995-08-02 | — | — | EP | disclosed |
| EP-0483465-B1 | Long chain di(acyloxy)dialkylsilanes, di(acyloxy)diarylsilanes, di(acyloxy)dialkoxysilanes, and tetra(acyloxy)silanes, process for their preparation, their use for the preparation of vesicles, so produced vesicles and their use as vehicles for drugs | SALAMA ZOSER BOULIS DR (DE) | 1995-08-02 | — | — | EP | disclosed |
| EP-0483465-A1 | Long chain di(acyloxy)dialkylsilanes, di(acyloxy)diarylsilanes, di(acyloxy)dialkoxysilanes, and tetra(acyloxy)silanes, process for their preparation, their use for the preparation of vesicles, so produced vesicles and their use as vehicles for drugs | Salama, Zoser Boulis, Dr. (DE) | 1992-05-06 | — | — | EP | disclosed |
| EP-0483465-A1 | Long chain di(acyloxy)dialkylsilanes, di(acyloxy)diarylsilanes, di(acyloxy)dialkoxysilanes, and tetra(acyloxy)silanes, process for their preparation, their use for the preparation of vesicles, so produced vesicles and their use as vehicles for drugs | Salama, Zoser Boulis, Dr. (DE) | 1992-05-06 | — | — | EP | disclosed |
| EP-0483465-A1 | Long chain di(acyloxy)dialkylsilanes, di(acyloxy)diarylsilanes, di(acyloxy)dialkoxysilanes, and tetra(acyloxy)silanes, process for their preparation, their use for the preparation of vesicles, so produced vesicles and their use as vehicles for drugs | Salama, Zoser Boulis, Dr. (DE) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241393-B2 | Organosilicon carriers for use in treating infections and/or diseases caused by SARS viruses | ACE2, ACE, TMPRSS2 | TSHR 2747/4885ALDH1A1 3096/4885HPGD 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.